Illumina and Genpathway are joining forces to provide whole-genome ChIP sequencing. The combined services will help identify and quantify transcription-factor binding sites across the entire genome.
Samples will be prepared using Genpathway’s FactorPath ChIP assays and sequenced by Illumina’s Genome Analyzer through its sequencing services. Genpathway will do the final data analysis. The combined services will also include cell or tissue processing, antibody selection and qualification, and quality-control steps throughout the assay.
“One of the top applications for sequencing is ChIP, a notoriously time-consuming and difficult procedure,” points out Mary Harper, Ph.D., CSO of Genpathway. “Combining Genpathway’s expertise in ChIP and data-analysis services with Illumina’s high-throughput next-generation sequencing technology and services provides researchers a faster path to discovery.”